Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy

Figures & data

Table 1 Demographic characteristics of the study population (N = 634)

Characteristic	Value
Gender, n (%)
Male	355 (56.2)
Female	277 (43.8)
Age, years
Mean ± standard deviation	63.0 ± 11.4
Range	23–89
Country, n (%)
France	162 (25.6)
Germany	230 (36.3)
Italy	158 (24.9)
United Kingdom	84 (13.3)
Ethnicity, n (%)
White	595 (94.2)
Non-white	37 (5.9)
Employment status, n (%)
Full-time	128 (20.5)
Part-time	11 (1.8)
Homemaker	59 (9.4)
Retired	365 (58.3)
Unemployed	63 (10.1)
Body mass index
Mean ± standard deviation, kg/m^2	27.2 ± 4.8
≥30, n (%)	318 (50.4)
Time since diagnosis, years
Mean standard deviation	1.8 ± 2.1
Range	0–17.3
Common comorbidities (≥5% of patients), n (%)
Hypertension	369 (58.2)
Hypercholesterolemia	246 (38.8)
Cardiovascular conditions	110 (17.4)
Sleep disorders	107 (16.9)
Osteoarthritis	95 (15.0)
Clinical depression	86 (13.6)
Feelings of depression	66 (10.4)
Clinical anxiety	48 (7.8)
Feelings of anxiety	44 (6.9)

Note: Numbers may not add up to 634 because of missing data.

Figure 1 Proportion of patients rating their painful diabetic peripheral neuropathy as mild, moderate, and severe.

Table 2 Physician-reported versus patient-reported severity of painful diabetic neuropathy as a condition (weighted kappa coefficient = 0.43; 95% confidence interval 0.37, 0.48)

Patient-reported severity		Physician-reported severity, n			Row total, n (%)	pDPN severity discordance, percent of patients
		Mild	Moderate	Severe*
Mild	Frequency	80	52	6	138 (22.0)	42.0
Moderate	Frequency	45	268	70	383 (61.2)	30.0
Severe	Frequency	3	46	56	105 (16.8)	46.7
Column total, n (%)		128 (20.5)	366 (58.5)	132 (21.1)	626 (100)	35.5

* Note: Includes “very severe” (n = 8).

Abbreviation: pDPN, painful diabetic peripheral neuropathy.

Figure 2 Relationship between self-reported severity of painful diabetic peripheral neuropathy and the Brief Pain Inventory Severity Indices.

Notes: *,^†P < 0.0001 for all pairwise comparisons between severity levels.

Figure 3 Relationship between self-reported severity of painful diabetic peripheral neuropathy and impact of pain on sleep.

Notes: P < 0.0001 for overall effect within patient and physician ratings; *,^†P < 0.0001 for all pairwise comparisons between severity levels.
Abbreviations: CI, confidence interval; pDPN, painful diabetic peripheral neuropathy.

Figure 4 Relationship between self-reported severity of painful diabetic peripheral neuropathy and productivity assessed using the Work Productivity and Activity Impairment (WPAI) scale.²⁷

Notes: *P < 0.05; ^†P < 0.001 for overall effect.
Abbreviation: CI, confidence interval.

Figure 5 Relationship between self-reported severity of painful diabetic peripheral neuropathy and indirect costs resulting from lost productivity.

Notes: *P < 0.05 for all pairwise comparisons between severity levels; P = 0.002 for overall effect.
Abbreviation: pDPN, painful diabetic peripheral neuropathy.

Reilly MCZ AS Dukes EM The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 1993 4 5 353 365 10146874

 PubMed Web of Science ®Google Scholar